{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:50:27Z","timestamp":1789901427580,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ahj.2015.09.007","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T04:14:40Z","timestamp":1442376880000},"page":"1061-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial"],"prefix":"10.1016","volume":"170","clinical-trial-number":[{"clinical-trial-number":"nct01687998","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bryan","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venugopal","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Tall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"McErlean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Riesmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Vangerow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Ruotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govinda J.","family":"Weerakkody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2015.09.007_bb0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.09.007_bb0010","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0015","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1161\/01.ATV.0000080687.94313.67","article-title":"Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db\/db mice","volume":"23","author":"MacLean","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0020","doi-asserted-by":"crossref","first-page":"36912","DOI":"10.1074\/jbc.274.52.36912","article-title":"Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice","volume":"274","author":"Foger","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2015.09.007_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1194\/jlr.M100440-JLR200","article-title":"Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice","volume":"44","author":"Cazita","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ahj.2015.09.007_bb0030","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1194\/jlr.M600135-JLR200","article-title":"Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice","volume":"47","author":"Casquero","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ahj.2015.09.007_bb0035","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI118255","article-title":"Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene","volume":"96","author":"Hayek","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2015.09.007_bb0040","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/ATVBAHA.110.205153","article-title":"Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency","volume":"30","author":"Hildebrand","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/364073a0","article-title":"Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein","volume":"364","author":"Marotti","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2015.09.007_bb0050","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/01.ATV.19.4.1105","article-title":"Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression","volume":"19","author":"Plump","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0055","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1161\/01.ATV.0000243925.65265.3c","article-title":"Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice","volume":"26","author":"Westerterp","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0060","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/70956","article-title":"Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein","volume":"5","author":"Herrera","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.ahj.2015.09.007_bb0065","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0070","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","article-title":"Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits","volume":"273","author":"Sugano","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2015.09.007_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2015.09.007_bb0080","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.M600332-JLR200","article-title":"Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits","volume":"48","author":"Morehouse","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ahj.2015.09.007_bb0085","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/342448a0","article-title":"Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins","volume":"342","author":"Brown","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2015.09.007_bb0090","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.09.007_bb0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0100","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.109.872705","article-title":"Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community","volume":"120","author":"Vasan","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.09.007_bb0105","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.109.875013","article-title":"Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study","volume":"121","author":"Ritsch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.09.007_bb0110","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/01.CIR.0000141730.65972.95","article-title":"Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study","volume":"110","author":"Boekholdt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.09.007_bb0115","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2015.09.007_bb0120","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.09.007_bb0125","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.09.007_bb0130","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.09.007_bb0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.09.007_bb0140","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.09.007_bb0145","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.09.007_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.ATV.0000256728.60226.77","article-title":"The failure of torcetrapib: was it the molecule or the mechanism?","volume":"27","author":"Tall","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0155","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.09.007_bb0160","doi-asserted-by":"crossref","first-page":"10E","DOI":"10.1016\/j.amjcard.2009.09.014","article-title":"Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial","volume":"104","author":"Barter","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0165","doi-asserted-by":"crossref","first-page":"32E","DOI":"10.1016\/j.amjcard.2009.09.017","article-title":"The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors","volume":"104","author":"Vergeer","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0170","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0175","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurheartj\/ehu105","article-title":"The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2015.09.007_bb0180","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial","volume":"33","author":"Luscher","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2015.09.007_bb0185","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.09.007_bb0190","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.09.007_bb0195","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1172\/JCI42946","article-title":"Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease","volume":"121","author":"Besler","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2015.09.007_bb0200","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib","volume":"8","author":"Tardif","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ahj.2015.09.007_bb0205","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.09.007_bb0210","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2015.09.007_bb0215","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/psp.2013.70","article-title":"The pharmacokinetics and pharmacokinetic\/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins","volume":"3","author":"Friedrich","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ahj.2015.09.007_bb0220","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315005931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315005931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:54:58Z","timestamp":1757570098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870315005931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0002870315005931"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2015.09.007","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2015.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}